Patents by Inventor Sandra Giannini
Sandra Giannini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240299474Abstract: The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.Type: ApplicationFiled: April 29, 2024Publication date: September 12, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Marie-Paule Simone Jeanne Feron, Sandra Giannini
-
Patent number: 12076352Abstract: The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.Type: GrantFiled: June 18, 2019Date of Patent: September 3, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Marie-Paule Simone Jeanne Feron, Sandra Giannini
-
Patent number: 11998579Abstract: The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.Type: GrantFiled: January 3, 2017Date of Patent: June 4, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Marie-Paule Simone Jeanne Feron, Sandra Giannini
-
Publication number: 20230293659Abstract: The application discloses a truncated Fusobacterium nucleatum Fusobacterium adhesin A (FadA) protein wherein at least a signal peptide which is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:8 is deleted from the N-terminus of the FadA protein. Polynucleotides and vectors encoding the truncated FadA protein and bacteriophage comprising a gene encoding FadA as well of methods of treating or preventing disease such as colorectal cancer or periodontitis are also disclosed in the application.Type: ApplicationFiled: July 30, 2021Publication date: September 21, 2023Inventors: Cindy CASTADO, Sandra GIANNINI
-
Patent number: 11466292Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.Type: GrantFiled: September 27, 2017Date of Patent: October 11, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Wivine Burny, Cindy Castado, Sandra Giannini, Julien Thierry Massaux
-
Patent number: 11266733Abstract: Nucleotide constructs encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, immunogenic compositions comprising such constructs and a pharmaceutically acceptable carrier, and uses thereof.Type: GrantFiled: September 25, 2018Date of Patent: March 8, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Wivine Burny, Cindy Castado, Sandra Giannini, Julien Thierry Massaux
-
Publication number: 20210252081Abstract: The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.Type: ApplicationFiled: June 18, 2019Publication date: August 19, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Marie-Paule Simone Jeanne FERON, Sandra GIANNINI
-
Patent number: 11040095Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.Type: GrantFiled: October 5, 2017Date of Patent: June 22, 2021Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
-
Publication number: 20200230226Abstract: Nucleotide constructs encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, immunogenic compositions comprising such constructs and a pharmaceutically acceptable carrier, and uses thereof.Type: ApplicationFiled: September 25, 2018Publication date: July 23, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Wivine BURNY, Cindy CASTADO, Sandra GIANNINI, Julien Thierry MASSAUX
-
Publication number: 20200123571Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.Type: ApplicationFiled: September 27, 2017Publication date: April 23, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Wivine BURNY, Cindy CASTADO, Sandra GIANNINI, Julien Thierry MASSAUX
-
Publication number: 20190224303Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.Type: ApplicationFiled: October 5, 2017Publication date: July 25, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Catherine Marie Ghislaine GERARD, Sandra Giannini, Julien Thierry MASSAUX
-
Publication number: 20190083552Abstract: The present invention discloses a recombinant bacteriophage comprising a phage genome polynucleotide including a gene encoding a heterologous antigen protein(s) and a killing gene encoding a protein that is capable of killing a host bacterium. Such a recombinant bacteriophage is designed to prime a subject's immune response and to kill the bacterium that it infects such that the “prime and kill” bacteriophage provides two lines of protection against infectious disease.Type: ApplicationFiled: January 3, 2017Publication date: March 21, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Christiane Marie-Paule Simon Jeanne FERON, Sandra GIANNINI
-
Publication number: 20150110824Abstract: The disclosure provides immunogenic compositions comprising HPV VLPs from one or more HPV types in combination with an adjuvant comprising a TLR agonist for use in a method for the prevention of HPV infection or disease in an individual, wherein a first dose of the immunogenic composition comprising HPV VLPs and a TLR agonist, is administered followed by a second dose of an immunogenic composition comprising HPV VLPs from one or more HPV types but which does not comprise a TLR agonist.Type: ApplicationFiled: March 18, 2013Publication date: April 23, 2015Inventors: Brigitte Desiree Alberte Colau, Sandra Giannini, Laurence Lockman
-
Publication number: 20120087937Abstract: This disclosure provides novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease. The constructs are chimeric proteins comprising L1 proteins with an HPV L2 peptide inserted in to the L1 protein. Such chimeric proteins may be formulated into immunogenic e.g., vaccine compositions, and optionally formulated with HPV L1 VLP based vaccines.Type: ApplicationFiled: June 24, 2010Publication date: April 12, 2012Inventors: Brigitte Desiree Alberte Colau, Najoua Dendouga, Sandra Giannini, Nicolas Pierri Fernand Lecrenier, Guy Jean Marie Fernand Pierre Baudoux
-
Publication number: 20110189229Abstract: The use of HPV 16 and HPV 18 virus like particles (VLPs) together with a pharmaceutically acceptable excipient, in a vaccine for the prevention of human papillomavirus related disease or infection, wherein the vaccine is formulated for administration according to a two dose regimen consisting of a first dose and a second dose.Type: ApplicationFiled: July 29, 2009Publication date: August 4, 2011Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Dominique Descamps, Sandra Giannini, Nicolas Lecrenier, Jean Stephenne, Martine Anne Cecile Wettendorff
